Related Experiment Videos
Roxithromycin and erythromycin in chlamydia-negative non-gonococcal urethritis.
1Department of Dermato-Venereology, Bispebjerg Hospital, Copenhagen, Denmark.
Acta Dermato-Venereologica
|January 1, 1990
Summary
Roxithromycin and erythromycin showed similar clinical efficacy for non-gonococcal urethritis. Both antibiotics were well-tolerated, with comparable gastrointestinal side effects in men.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Non-gonococcal urethritis (NGU) is a common infection in men.
- Antibiotic resistance necessitates evaluating alternative treatment options.
- Macrolides are frequently used for bacterial infections.
Purpose of the Study:
- To compare the clinical efficacy and safety of roxithromycin versus erythromycin in treating chlamydia-negative NGU.
- To assess treatment outcomes at early (day 8) and later (day 21) time points.
Main Methods:
- A comparative study involving 87 men diagnosed with chlamydia-negative NGU.
- Patients were randomized to receive either roxithromycin 300 mg once daily or erythromycin 500 mg twice daily.
- Clinical efficacy was assessed by evaluating symptom resolution and microbiological cure.
Main Results:
- Clinical efficacy rates were high for both treatments: roxithromycin (88% on day 8, 78-84% on day 21) and erythromycin (98% on day 8, 86% on day 21).
- The observed differences in efficacy between the two antibiotic groups were not statistically significant.
- Gastrointestinal side effects were reported in approximately 15% of patients in both treatment arms, indicating similar safety profiles.
Conclusions:
- Roxithromycin 300 mg once daily is a viable alternative to erythromycin 500 mg twice daily for treating chlamydia-negative non-gonococcal urethritis.
- Both regimens demonstrate comparable clinical effectiveness and safety profiles, with manageable gastrointestinal side effects.